INFLIXIMAB-ABDA

Course overview

INFLIXIMAB (IFX) IS A BIOLOGIC AGENT THAT SPECIFICALLY TARGETS AN IMMUNE MEDIATOR, TUMOR NECROSIS FACTOR ALPHA (TNFA), INVOLVED IN A PATHOLOGICAL PROCESS. ANTI TNFA AGENTS HAVE ENJOYED USE AS THERAPEUTIC MODALITIES SINCE 1998; HOWEVER, THEIR FIRST USE IN DERMATOLOGY DATES BACK TO 2002 WHEN THEY FIRST SAW USE IN THE TREATMENT OF PSORIASIS. FDA-APPROVED INDICATIONS INCLUDE CROHN DISEASE, ULCERATIVE COLITIS, RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS, PSORIATIC ARTHRITIS, PLAQUE PSORIASIS, AND JUVENILE IDIOPATHIC ARTHRITIS. THIS ACTIVITY DESCRIBES THE MODE OF ACTION OF INFLIXIMAB-ABDA, INCLUDING ADVERSE EVENT PROFILES, AND OTHER KEY FACTORS E.G. DOSING, PHARMACODYNAMICS, PHARMACOKINETICS, MONITORING, AND HIGHLIGHTS THE ROLE OF THE INTERPROFESSIONAL TEAM IN THE MANAGEMENT OF THESE PATIENTS.